肝炎治療薬の世界市場:A型肝炎、B型肝炎、C型肝炎...市場調査レポートについてご紹介

【英文タイトル】Global Hepatitis Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Product offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Classification
• Mode of transmission
• Epidemiology
• Diagnosis
• Symptoms
• Treatment

PART 06: Key marketed drugs
• Hepatitis A
• Hepatitis B
• Hepatitis C

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type
• Hepatitis A
• Hepatitis B
• Hepatitis C

PART 09: Market segmentation by MOA
• Virus-specific agents
• Non-specific agents

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape
• Competitive scenario
• Gilead Sciences
• Johnson & Johnson
• F. Hoffman-La Roche
• Merck
• GlaxoSmithKline
• Vertex Pharmaceuticals
• Novartis
• Other prominent vendors

PART 17: Key vendor analysis
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Roche
• Vertex Pharmaceuticals

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Mode of transmission and incubation period of different types of hepatitis
Exhibit 02: Risk factors for hepatitis A transmission
Exhibit 03: Risk factors for hepatitis B transmission
Exhibit 04: Risk factors for hepatitis C transmission
Exhibit 05: Worldwide endemicity of HAV infection
Exhibit 06: Endemicity pattern of HBV worldwide
Exhibit 07: Prevalence of HBV in APAC
Exhibit 08: Acute hepatitis B infection by age group 2005-2013
Exhibit 09: Prevalence of hepatitis B in US 2005-2013
Exhibit 10: Estimated HBV incidence rates in APAC countries 2004
Exhibit 11: Prevalence rates of hepatitis C across different regions 2012
Exhibit 12: Antibodies indicating different hepatitis types
Exhibit 13: Tests for viral proteins and generic materials
Exhibit 14: Screening tests for hepatitis B infection
Exhibit 15: Screening tests for hepatitis C infection
Exhibit 16: Types of hepatitis and symptoms
Exhibit 17: Recommended dosages and schedules for hepatitis A vaccines
Exhibit 18: Recommended dosages and schedules for hepatitis B vaccines
Exhibit 19: Combination vaccines for hepatitis A and/or hepatitis B
Exhibit 20: Hepatitis A: Key marketed vaccines
Exhibit 21: Hepatitis B: Key marketed drugs
Exhibit 22: Hepatitis C: Key marketed drugs
Exhibit 23: Global hepatitis drugs market 2014-2019 ($ billions)
Exhibit 24: Five forces analysis
Exhibit 25: Market segmentation by type
Exhibit 26: Global hepatitis A drugs market 2014-2019 ($ billions)
Exhibit 27: Global hepatitis B drugs market 2014-2019 ($ billions)
Exhibit 28: Global hepatitis C drugs market 2014-2019 ($ billions)
Exhibit 29: Snapshot of global hepatitis drugs market
Exhibit 30: Classification of global hepatitis drugs market by MOA
Exhibit 31: Global hepatitis drugs market by geographical segmentation 2014
Exhibit 32: List of key drivers
Exhibit 33: List of key challenges
Exhibit 34: Impact of drivers and challenges
Exhibit 35: List of key trends
Exhibit 36: Gilead: Pipeline candidates for hepatitis B
Exhibit 37: Gilead Sciences: Pipeline candidates for hepatitis C
Exhibit 38: Gilead Sciences: Key takeaways
Exhibit 39: Johnson & Johnson: Global YoY revenue of Incivo 2012-2014 ($ millions)
Exhibit 40: Johnson & Johnson: Global revenue of Olysio 2014 ($ millions)
Exhibit 41: Johnson & Johnson: Key takeaways
Exhibit 42: Roche: Pipeline candidates for hepatitis C
Exhibit 43: F. Hoffman-La Roche: Key takeaways
Exhibit 44: Merck: Global YoY revenue of Victrelis 2011-2013 ($ millions)
Exhibit 45: Merck: Pipeline candidates for hepatitis C
Exhibit 46: Merck: Key takeaways
Exhibit 47: GlaxoSmithKline: Pipeline candidates for hepatitis B
Exhibit 48: GlaxoSmithKline: Pipeline candidates for hepatitis C
Exhibit 49: GlaxoSmithKline: Key takeaways
Exhibit 50: Vertex Pharmaceuticals: Global YoY revenue of Incivek 2011-2013 ($ millions)
Exhibit 51: Vertex Pharmaceuticals: Pipeline candidates for hepatitis C
Exhibit 52: Vertex Pharmaceuticals: Key takeaways
Exhibit 53: Novartis: Key takeaways
Exhibit 54: Gilead Sciences: List of key drugs
Exhibit 55: GlaxoSmithKline: Segmentation by product 2014
Exhibit 56: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 57: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 58: Johnson & Johnson: Business segmentation
Exhibit 59: Johnson & Johnson: Key products of medical devices segment
Exhibit 60: Johnson & Johnson: Medical devices segmentation by revenue 2014
Exhibit 61: Merck: Business segmentation
Exhibit 62: Merck: Geographical segmentation
Exhibit 63: Business segmentation by revenue
Exhibit 64: Novartis: Business segmentation
Exhibit 65: Novartis: Geographical segmentation
Exhibit 66: Novartis: Business segmentation by revenue
Exhibit 67: Roche: Business segments
Exhibit 68: Roche: Pharmaceuticals segmentation
Exhibit 69: Roche: Revenue comparison by business segment
Exhibit 70: Roche: Geographical segmentation
Exhibit 71: Vertex Pharmaceuticals: Product segmentation by revenue
Exhibit 72: Vertex Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 73: Vertex Pharmaceuticals: Geographical segmentation


【レポート販売概要】

■ タイトル:肝炎治療薬の世界市場:A型肝炎、B型肝炎、C型肝炎
■ 英文:Global Hepatitis Drugs Market 2015-2019
■ 発行日:2015年12月9日
■ 調査会社:Technavio
■ 商品コード:IRTNTR6912
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。